In summary, these findings confirm that mGPDH negatively regulates melanoma metastasis by modulating the NRF2 signalling pathway and provide several insights into mGPDH‐based targeted therapy to inhibit NRF2, which might be an attractive anti‐melanoma treatment approach in the future. Here, GPD2 is linked to melanoma.